Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Express Scripts
Cerilliant
Daiichi Sankyo
UBS
Argus Health
McKinsey
Teva
Cantor Fitzgerald

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,579,019

« Back to Dashboard

Summary for Patent: 7,579,019
Title:Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
Abstract:The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components.
Inventor(s): Tapolsky; Gilles H. (The Woodlands, TX), Osborne; David W. (The Woodlands, TX)
Assignee: Arius Two, Inc. (Raleigh, NC)
Application Number:11/069,089
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,579,019
Patent Claim Types:
see list of patent claims
Use; Formulation; Delivery; Device;

Drugs Protected by US Patent 7,579,019

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bdsi BELBUCA buprenorphine hydrochloride FILM;BUCCAL 207932-001 Oct 23, 2015 RX Yes No ➤ Sign Up ➤ Sign Up TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE ➤ Sign Up
Bdsi BELBUCA buprenorphine hydrochloride FILM;BUCCAL 207932-002 Oct 23, 2015 RX Yes No ➤ Sign Up ➤ Sign Up TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE ➤ Sign Up
Bdsi BELBUCA buprenorphine hydrochloride FILM;BUCCAL 207932-003 Oct 23, 2015 RX Yes No ➤ Sign Up ➤ Sign Up TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE ➤ Sign Up
Bdsi BELBUCA buprenorphine hydrochloride FILM;BUCCAL 207932-004 Oct 23, 2015 RX Yes No ➤ Sign Up ➤ Sign Up TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,579,019

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,800,832 Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces ➤ Sign Up
6,159,498 Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Federal Trade Commission
Colorcon
Chubb
Fish and Richardson
Accenture
Cipla
Fuji
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.